BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Assembly Biosciences (ASMB)Assembly BiosciencesConference / presentation

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co.

Related news

ASMBAssembly Biosciences2026-05-11 12:00 EST

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

SPROSpero Therapeutics2026-09-02 21:01 EST

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

AVIRAtea2026-09-08 11:00 EST

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

MBRXMoleculin Biotech, Inc.2026-09-11 12:30 EST

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

MBRXMoleculin Biotech, Inc.2026-03-17 13:05 EST

Moleculin to Present at 38th Annual ROTH Conference

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

ASMBAssembly Biosciences2026-08-13 20:00 EST

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Stock data

Close
25.34 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States